Drugs / Rimeporide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02710591 | Mar 2016 → Dec 2017 | Duchenne muscular dystrophy | EspeRare Foundation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rimeporide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02710591 ↗ |
| Known as | Rimeporida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107802 ↗ |
| Action | Inhibit | “NHE-1 inhibition with Rimeporide represents a new therapeutic approach” NCT02710591 ↗ |
| Modality | Small molecule | — CHEMBL2107802 ↗ |
| Route | Oral | “Rimeporide will be taken orally for 4 weeks, three times a day.” NCT02710591 ↗ |